BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 21333932)

  • 1. Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.
    Tyrrell J; Campbell SM; Curnow A
    Photodiagnosis Photodyn Ther; 2011 Mar; 8(1):30-8. PubMed ID: 21333932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
    Tyrrell JS; Campbell SM; Curnow A
    Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT.
    Tyrrell J; Campbell S; Curnow A
    Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):86-97. PubMed ID: 20510303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
    Tyrrell JS; Morton C; Campbell SM; Curnow A
    Br J Dermatol; 2011 Jun; 164(6):1362-8. PubMed ID: 21564050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative study of in vivo protoporphyrin IX fluorescence build up during occlusive treatment phases.
    Campbell CL; Brown CTA; Wood K; Salvio AG; Inada NM; Bagnato VS; Moseley H
    Photodiagnosis Photodyn Ther; 2017 Jun; 18():204-207. PubMed ID: 28257944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage.
    Heerfordt IM; Bieliauskiene G; Wulf HC
    Photodiagnosis Photodyn Ther; 2018 Jun; 22():155-157. PubMed ID: 29601904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device.
    Blake E; Campbell S; Allen J; Mathew J; Helliwell P; Curnow A
    J Photochem Photobiol B; 2012 Dec; 117():97-103. PubMed ID: 23092624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.
    Tyrrell J; Campbell S; Curnow A
    Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):232-8. PubMed ID: 21112545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions.
    Blake E; Allen J; Curnow A
    Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):575-82. PubMed ID: 24284114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin.
    Lesar A; Ferguson J; Moseley H
    Photodermatol Photoimmunol Photomed; 2009 Aug; 25(4):191-5. PubMed ID: 19614897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
    Blake E; Allen J; Thorn C; Shore A; Curnow A
    Lasers Med Sci; 2013 May; 28(3):997-1005. PubMed ID: 22926533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin.
    Middelburg TA; de Bruijn HS; van der Ploeg-van den Heuvel A; Neumann HA; Robinson DJ
    Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):703-9. PubMed ID: 24284130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses.
    Fauteck JD; Ackermann G; Birkel M; Breuer M; Moor AC; Ebeling A; Ortland C
    Arch Dermatol Res; 2008 Feb; 300(2):53-60. PubMed ID: 17960406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porphyrin biodistribution in UV-exposed murine skin after methyl- and hexyl-aminolevulinate incubation.
    Togsverd-Bo K; Lerche CM; Philipsen PA; Poulsen T; Wulf HC; Haedersdal M
    Exp Dermatol; 2012 Apr; 21(4):260-4. PubMed ID: 22320713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate.
    de Bruijn HS; Meijers C; van der Ploeg-van den Heuvel A; Sterenborg HJ; Robinson DJ
    J Photochem Photobiol B; 2008 Aug; 92(2):91-7. PubMed ID: 18571933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen saturation and perfusion changes during dermatological methylaminolaevulinate photodynamic therapy.
    Tyrrell J; Thorn C; Shore A; Campbell S; Curnow A
    Br J Dermatol; 2011 Dec; 165(6):1323-31. PubMed ID: 21801159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Physical Pretreatment Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: A Randomized Clinical Trial.
    Bay C; Lerche CM; Ferrick B; Philipsen PA; Togsverd-Bo K; Haedersdal M
    JAMA Dermatol; 2017 Apr; 153(4):270-278. PubMed ID: 28146245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
    Nissen CV; Heerfordt IM; Wiegell SR; Mikkelsen CS; Wulf HC
    Br J Dermatol; 2017 May; 176(5):1241-1246. PubMed ID: 27696393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
    Anayo L; Magnussen A; Perry A; Wood M; Curnow A
    Lasers Surg Med; 2018 Jul; 50(5):552-565. PubMed ID: 29603761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protoporphyrin IX formation after topical application of methyl aminolaevulinate and BF-200 aminolaevulinic acid declines with age.
    Nissen CV; Philipsen PA; Wulf HC
    Br J Dermatol; 2015 Sep; 173(3):760-6. PubMed ID: 25997508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.